Last reviewed · How we verify
GC1102
At a glance
| Generic name | GC1102 |
|---|---|
| Also known as | Hepabig_Gene |
| Sponsor | Green Cross Corporation |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102 (PHASE2, PHASE3)
- A Study of GC1102(Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients (PHASE2)
- A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients (PHASE1)
- A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients (PHASE2)
- Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GC1102 CI brief — competitive landscape report
- GC1102 updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI